CN115969802A - 含吡非尼酮缓释组合物用于治疗和逆转人脂肪性肝炎的药物用途 - Google Patents

含吡非尼酮缓释组合物用于治疗和逆转人脂肪性肝炎的药物用途 Download PDF

Info

Publication number
CN115969802A
CN115969802A CN202211265065.XA CN202211265065A CN115969802A CN 115969802 A CN115969802 A CN 115969802A CN 202211265065 A CN202211265065 A CN 202211265065A CN 115969802 A CN115969802 A CN 115969802A
Authority
CN
China
Prior art keywords
administered
release tablet
extended release
weeks
pirfenidone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202211265065.XA
Other languages
English (en)
Chinese (zh)
Inventor
J.S.阿门达里兹博伦达
J.A.R.马加纳卡斯特罗
N.赫南德兹阿尔达纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exkaliber Pharmaceutical Co ltd
Original Assignee
Exkaliber Pharmaceutical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exkaliber Pharmaceutical Co ltd filed Critical Exkaliber Pharmaceutical Co ltd
Publication of CN115969802A publication Critical patent/CN115969802A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202211265065.XA 2016-11-11 2017-11-09 含吡非尼酮缓释组合物用于治疗和逆转人脂肪性肝炎的药物用途 Pending CN115969802A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
MX2016014775A MX364040B (es) 2016-11-11 2016-11-11 Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld/nash).
MXMX/A/2016/014775 2016-11-11
CN201780076430.3A CN110248646A (zh) 2016-11-11 2017-11-09 包含吡非尼酮的缓释组合物用于治疗和逆转人脂肪性肝炎(nafld/nash)的药物用途
PCT/MX2017/000129 WO2018088886A1 (es) 2016-11-11 2017-11-09 Uso farmacéutico de una composición que contiene pirfenidona de liberación prolongada (pfd-lp) para la reversión y tratamiento de la esteatohepatitis humana (nafld/nash)

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201780076430.3A Division CN110248646A (zh) 2016-11-11 2017-11-09 包含吡非尼酮的缓释组合物用于治疗和逆转人脂肪性肝炎(nafld/nash)的药物用途

Publications (1)

Publication Number Publication Date
CN115969802A true CN115969802A (zh) 2023-04-18

Family

ID=61193005

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202211265065.XA Pending CN115969802A (zh) 2016-11-11 2017-11-09 含吡非尼酮缓释组合物用于治疗和逆转人脂肪性肝炎的药物用途
CN201780076430.3A Pending CN110248646A (zh) 2016-11-11 2017-11-09 包含吡非尼酮的缓释组合物用于治疗和逆转人脂肪性肝炎(nafld/nash)的药物用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201780076430.3A Pending CN110248646A (zh) 2016-11-11 2017-11-09 包含吡非尼酮的缓释组合物用于治疗和逆转人脂肪性肝炎(nafld/nash)的药物用途

Country Status (21)

Country Link
US (3) US20190262325A1 (enExample)
EP (1) EP3539537B1 (enExample)
JP (2) JP2019535822A (enExample)
KR (2) KR20240065330A (enExample)
CN (2) CN115969802A (enExample)
AR (1) AR110057A1 (enExample)
AU (3) AU2017358367B2 (enExample)
CA (1) CA3043300A1 (enExample)
CL (1) CL2019001280A1 (enExample)
CO (1) CO2019004799A2 (enExample)
EC (1) ECSP19031851A (enExample)
IL (1) IL266519A (enExample)
JO (1) JOP20190102A1 (enExample)
MA (1) MA45754A1 (enExample)
MX (1) MX364040B (enExample)
PE (1) PE20191149A1 (enExample)
PH (1) PH12019501047A1 (enExample)
RU (1) RU2019116422A (enExample)
UY (1) UY37478A (enExample)
WO (1) WO2018088886A1 (enExample)
ZA (1) ZA201903012B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007009796A (es) 2007-08-14 2009-02-25 Cell Therapy And Technology S Gel conteniendo pirfenidona.
MX2011007675A (es) 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
MX346763B (es) 2012-03-28 2017-03-31 Cell Therapy And Tech S A De C V Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné.
MX356551B (es) 2012-08-23 2018-06-04 Grupo Medifarma S A De C V Star Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné.
MX366086B (es) 2017-08-15 2019-06-27 Cell Therapy And Tech S A De C V Composicion topica semisolida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños cronicos de la piel.
JP2021504479A (ja) * 2017-11-28 2021-02-15 アイガー・バイオファーマシューティカルズ・インコーポレイテッドＥｉｇｅｒ Ｂｉｏｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 非アルコール性脂肪性肝炎の処置のための方法および医薬組成物
MX368750B (es) 2018-08-31 2019-10-15 Cell Therapy And Tech S A De C V Composiciones farmaceuticas semisolidas de base oleosa conteniendo pirfenidona para su aplicacion en la reparacion tisular.
WO2020115774A1 (en) 2018-12-06 2020-06-11 Cipla Limited High drug load extended release formulations
AU2021365528A1 (en) * 2020-10-23 2023-06-15 Hq Han Bifunctional antagonists of tumor necrosis factor-alpha and transforming growth factor-beta and uses thereof
CN116159056A (zh) * 2023-03-09 2023-05-26 中南大学湘雅医院 一种氟非尼酮在制备非酒精性脂肪性肝炎药物中的应用
CN117007806A (zh) * 2023-09-21 2023-11-07 中国人民解放军军事科学院军事医学研究院 靶向肝巨噬细胞内lxr用于控制慢乙肝进展

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005000227A2 (en) * 2003-06-06 2005-01-06 Intermune, Inc. Methods of treating tnf-mediated disorders
US20110288134A1 (en) * 2008-10-29 2011-11-24 Pacific Therapeutics Ltd. Composition and method for treating fibrosis
CN103957892A (zh) * 2011-07-19 2014-07-30 细胞治疗技术合伙股份有限公司 以缓释片剂形式制备含有吡非尼酮的药物组合物的方法及其在人慢性肾功能衰竭、乳房包膜挛缩和肝纤维化的复原中的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60234812D1 (de) * 2001-01-29 2010-02-04 Shionogi & Co Arzneipräparat, das als wirkstoff 5-methyl-1-phenyl-2-(1h)-pyridon enthält
CN100542532C (zh) * 2004-05-24 2009-09-23 上海睿星基因技术有限公司 吡非尼酮在制备治疗肝损伤坏死和急性肺损伤的药物中的用途
US7635707B1 (en) * 2008-11-10 2009-12-22 Intermune, Inc. Pirfenidone treatment for patients with atypical liver function
CN101972236A (zh) * 2010-10-13 2011-02-16 北京诚创康韵医药科技有限公司 一种含吡非尼酮的缓释制剂
CN102488660A (zh) * 2011-12-15 2012-06-13 西安天一秦昆制药有限责任公司 一种含吡非尼酮的缓释微丸
CN103550242B (zh) * 2013-11-22 2015-07-15 四川国康药业有限公司 一种治疗肝纤维化的药物组合物及其制备方法

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005000227A2 (en) * 2003-06-06 2005-01-06 Intermune, Inc. Methods of treating tnf-mediated disorders
US20080025986A1 (en) * 2003-06-06 2008-01-31 Ozes Osman N Methods of Treating Tnf-Mediated Disorders
US20110288134A1 (en) * 2008-10-29 2011-11-24 Pacific Therapeutics Ltd. Composition and method for treating fibrosis
CN103957892A (zh) * 2011-07-19 2014-07-30 细胞治疗技术合伙股份有限公司 以缓释片剂形式制备含有吡非尼酮的药物组合物的方法及其在人慢性肾功能衰竭、乳房包膜挛缩和肝纤维化的复原中的应用
US20140296300A1 (en) * 2011-07-19 2014-10-02 Cell Therapy and Technology S.A. DE C.V. Process for the preparation of a pharmaceutical composition containing pirfenidone in sustained-release tablet form and its application in the regression of human chronic renal failure, breast capsular contracture and hepatic fibrosis

Also Published As

Publication number Publication date
US20190262325A1 (en) 2019-08-29
KR20190084056A (ko) 2019-07-15
MX364040B (es) 2019-04-11
IL266519A (en) 2019-07-31
JP2019535822A (ja) 2019-12-12
US20250325530A1 (en) 2025-10-23
PE20191149A1 (es) 2019-09-02
AU2024200737A1 (en) 2024-02-22
JP2022173344A (ja) 2022-11-18
EP3539537B1 (en) 2026-07-15
EP3539537A1 (en) 2019-09-18
CO2019004799A2 (es) 2019-07-31
CA3043300A1 (en) 2018-05-17
RU2019116422A3 (enExample) 2021-04-09
RU2019116422A (ru) 2020-12-11
AR110057A1 (es) 2019-02-20
MA45754A1 (fr) 2019-12-31
AU2017358367B2 (en) 2023-11-09
CN110248646A (zh) 2019-09-17
MX2016014775A (es) 2018-05-10
US20230181550A1 (en) 2023-06-15
CL2019001280A1 (es) 2019-07-19
ECSP19031851A (es) 2019-06-30
WO2018088886A1 (es) 2018-05-17
AU2017358367A1 (en) 2019-05-30
PH12019501047A1 (en) 2019-12-11
ZA201903012B (en) 2020-09-30
KR20240065330A (ko) 2024-05-14
UY37478A (es) 2018-05-31
AU2026200298A1 (en) 2026-02-05
JOP20190102A1 (ar) 2019-05-06

Similar Documents

Publication Publication Date Title
US20250325530A1 (en) Pharmaceutical use of an extended-release composition containing pirfenidone for the treatment and reversal of human steatohepatitis (nafld/nash)
US11291694B2 (en) Composition for treating or preventing metabolic disease, containing, as active ingredient, extracellular vesicles derived from Akkermansia muciniphila bacteria
Boland et al. Towards a standard diet-induced and biopsy-confirmed mouse model of non-alcoholic steatohepatitis: Impact of dietary fat source
JP2023501058A (ja) ベータ－ラパコンを有効成分として含む胆汁うっ滞性肝疾患予防又は治療用薬学組成物
Bossenmeyer‐Pourié et al. Early methyl donor deficiency produces severe gastritis in mothers and offspring through N‐homocysteinylation of cytoskeleton proteins, cellular stress, and inflammation
CN116251096B (zh) Iaa和/或ila在制备治疗肥胖、局部脂肪堆积及其合并症的药物或护肤品中的用途
WO2019227764A1 (zh) 一种mln4924在制备治疗糖尿病和/或肥胖药物的新用途
Yaghchiyan et al. Histologic, metabolic, and inflammatory changes in the liver of high-fat diet-induced obese rats before and after vitamin D administration
CN113424795B (zh) 一种急性胰腺炎动物模型的构建方法和用途
JP2021527669A (ja) 線維症の軽減又は治療のための組成物及び方法
HK40092172A (en) Pharmaceutical use of an extended-release composition containing pirfenidone for the treatment and reversal of human steatohepatitis
AU2016360956A1 (en) IL-34 antisense oligonucleotides and methods of using same
CN103037901A (zh) 抑制cd36以控制肥胖和胰岛素敏感性
TW202110432A (zh) 包含１５—ＨＥＰＥ及／或１５—ＨＥＴｒＥ之組合物及治療或預防心血管代謝疾病、代謝症候群及／或相關疾病之方法
US12533394B2 (en) Compositions and methods for treating metabolic disorders
KR20250150676A (ko) 당뇨 제어 및 염증성장질환 치료의 향상을 위한 구조적으로 변형된 지방산
CN113402582B (zh) Ank三肽及其应用
CN112641779B (zh) Gw441756在制备预防和/或治疗脂肪肝药物中的应用
Abd-Elsattar et al. A Histological Study of The Protective Role of Intermittent Fasting and Probiotics on Indomethacin Induced Colitis in Adult Male Albino Rats
WO2023202439A1 (zh) 二萜化合物衍生物或其盐在制备防治特应性皮炎的药物中的应用
CN119970721A (zh) 吲哚乙酸在制备预防和/或治疗脂肪肝肝纤维化药物中的应用
Gaidos et al. Vitamin D deficiency in inflammatory bowel disease.
WO2016173487A1 (en) Method for improving kidney and/or heart function in patients with kidney disease
WO2019189676A1 (ja) ヒアルロン酸を有効成分として含むアレルゲン作用増強剤
Hida et al. Chromo-capsule endoscopy versus standard capsule endoscopy for the assessment of remaining small bowel lesions at the early postoperative period in Crohn's disease

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40092172

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20230418

WD01 Invention patent application deemed withdrawn after publication